Consequently, we conducted a comprehensive assessment of cancer genomic data to identify co-occurring genetic alterations in BRCA1/BRCA2 cancers, comparing them with wild-type histologic controls, to identify candidate genes that would be in a synthetic viable interaction with BRCA1 or BRCA2 loss-of-function (Fig. 1a). The gene discussed is BRCA1; the disease is cancer.